title: Newly impaired glucose metabolism and prognosis after percutaneous revascularization.
abstract: BACKGROUND
  Clinical practice guidelines recommend ad hoc screening of diabetes in patients admitted for macrovascular disease; however, these recommendations are rarely followed in real practice. This study was undertaken to assess whether impaired glucose metabolism, newly diagnosed after percutaneous coronary intervention (PCI) or known diabetes, provides prognostic information.
  
  
  METHODS
  We studied 374 patients who underwent PCI. An oral glucose tolerance test was carried out in the known non-diabetic patients with fasting glucose < 7 mmol/L.
  
  
  RESULTS
  Eighty-one percent of the patients presented impaired glucose metabolism, from which 35.3% were previously diagnosed with diabetics, 21.4% were newly detected diabetics, and 24.3% were pre-diabetics. After a mean follow-up of 35.8 ± 13.4 months, only a known history of diabetes was an independent predictor of revascularization (OR = 2.03, p = 0.025), non-fatal acute myocardial infarction (OR = 2.70, p = 0.029) and readmission due to heart failure during the follow-up (OR = 3.82, p = 0.022).
  
  
  CONCLUSIONS
  Screening for impaired glucose metabolism after PCI permits the detection of a high proportion of patients with abnormal glucose regulations. However, previously known diabetes remains the only independent predictor of cardiovascular events in the follow-up.
authors.affiliation: Unidad de Gestion Clinica del Corazón, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, University of Malaga, Malaga, Spain, Red de Investigación Cardiovascular (RIC); 2Medicine Department, School of Medicine, University of Malaga, Spain. mjimeneznavarro@gmail.com.
authors.forename: Manuel F
authors.initials: MF
authors.lastname: Jiménez-Navarro
authors.forename: Julia
authors.initials: J
authors.lastname: Fernández-Pastor
authors.forename: Lourdes
authors.initials: L
authors.lastname: Garrido-Sánchez
authors.forename: María J
authors.initials: MJ
authors.lastname: Molina-Mora
authors.forename: Carmen
authors.initials: C
authors.lastname: Ortiz-García
authors.forename: Juan H
authors.initials: JH
authors.lastname: Alonso-Briales
authors.forename: Alejandro
authors.initials: A
authors.lastname: Pérez-Cabeza
authors.forename: Jose M
authors.initials: JM
authors.lastname: Hernández-García
authors.forename: Eduardo
authors.initials: E
authors.lastname: de Teresa-Galván
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Tinahones
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D016009:Chi-Square Distribution; D003920:Diabetes Mellitus / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D005215:Fasting / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006333:Heart Failure / Q000209:etiology / Q000628:therapy; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000209:etiology / Q000628:therapy; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000628:therapy*; D016017:Odds Ratio; D010359:Patient Readmission; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D011236:Prediabetic State / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001786:Blood Glucose